Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar [Phase 1]

View source ↗

Summary

A Phase 1 trial completed in Burkina Faso and Madagascar evaluating the safety, tolerability, and immunogenicity of the Sm-p80 + GLA-SE vaccine candidate Schist…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schistosomiasis

Drugs mentioned

• SchistoShield (Sm-p80 + GLA-SE vaccine)

Snippet

Sponsor: International Vaccine Institute | Conditions: Schistosomiasis | Phase 1 | Status: COMPLETED